Antitumor response against breast cancer

Joaquín Arribas, researcher of the Vall d’Hebrón, of Icrea and director of the IMIM.

Techniques like chemotherapy o to radiotherapy do not completely prevent the recurrence of breast cancer to patients, and a study led by the Sea Hospital will carry out a strategy to reverse this situation. The project will attack a specific type of tumor cell and, if there is sufficient evidence, will initiate a clinical trial in patients from the year 2025.

The study, led by research professor at the Catalan Institution for Research and Advanced Studies (Icrea), from Sea Hospital and of Hebron Valley, Joaquin Arribasseeks to completely eliminate the tumor cells to prevent them from acting again in time. The researcher states Medical Writing “It has been known for less than a decade that many tumor-fighting therapies do not kill tumor cells. Many chemotherapies y radiotherapy they induce a cellular state, but not the death of these cells. These stop proliferate and inhibited, but they are still alive. This scenario is known as cellular senescence. There is an antitumor response at the beginning, but since they are still viable, the cells are modified and prepare the tumor to generate a recurrence later”.

meet the functioning and the mechanism of these cells to eliminate them is the goal that the group of researchers led by Arribas at the Hospital del Mar will pursue for three years. “We are looking for a kind of double hit to the tumorfirst with a antitumor responseto stop proliferating, and then try to eliminate them so that the unwanted effect, which is the regrowth of the tumor. These cells do not proliferate, but they encourage neighboring cells to do so”.

Read also  Five healthy foods that are eaten incorrectly

“We look for a kind of double blow to the tumor, first with an antitumor response and then try to eliminate them”

To carry out this strategy, the researchers not only act with cellsbut rather, in the words of Arribas, “a mouse model that we can eliminate the indecent cells and thus define what is the ideal time to eliminate them after endowing the tumors. Once we have this experience with animals, we will try to develop strategies at the end of the project to eliminate these cells in patients and be able to carry out a clinical trial”.

In search of a durable antitumor response

The project will last a total of three years and after this period of time, Arribas has “sufficient evidence on when these cells must be eliminated to obtain a antitumor response much more durable and some idea of ​​how to eliminate them in patients. The project will start at the end of 2022 and will end in 2025, when we will seek to apply it to patients”.

“The project will start at the end of 2022 and will end in 2025”

The breast cancer project, financed by La Caixa, will be carried out at the Hospital del Mar, although it will also have the collaboration of the Vall d’Hebrón Institute of Oncology. Preventing the recurrence of breast cancer is no longer a chimera, and in 2025 the moment of truth will come with the opening of a more than possible clinical trial.

Although it may contain statements, data or notes from health institutions or professionals, the information contained in Medical Writing is edited and prepared by journalists. We recommend the reader that any questions related to health be consulted with a health professional.